Pablo Canales-Herrerias, Mathieu Uzzan, Akihiro Seki, Rafael S Czepielewski, Bram Verstockt, Alexandra E Livanos, Fiona Raso, Alexandra Dunn, Daniel Dai, Andrew Wang, Zainab Al-Taie, Jerome Martin, Thomas Laurent, Huaibin M Ko, Minami Tokuyama, Michael Tankelevich, Hadar Meringer, Francesca Cossarini, Divya Jha, Azra Krek, John D Paulsen, Matthew D Taylor, Mohammad Zuber Nakadar, Joshua Wong, Emma C Erlich, Rachel L Mintz, Emily J Onufer, Beth A Helmink, Keshav Sharma, Adam Rosenstein, Danielle Ganjian, Grace Chung, Travis Dawson, Julius Juarez, Vijay Yajnik, Andrea Cerutti, Jeremiah J Faith, Mayte Suarez-Farinas, Carmen Argmann, Francesca Petralia, Gwendalyn J Randolph, Alexandros D Polydorides, Andrea Reboldi, Jean-Frederic Colombel, Saurabh Mehandru
Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the α4β7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of VDZ, we examined five distinct cohorts of patients with UC. A decrease in naïve B and T cells in the intestines and gut-homing (β7+ ) plasmablasts in circulation of VDZ-treated patients suggested that VDZ targets gut-associated lymphoid tissue (GALT). Anti-α4β7 blockade in wild-type and photoconvertible (KikGR) mice confirmed a loss of GALT size and cellularity because of impaired cellular entry...
April 19, 2024: Science Immunology